

Claims

1. A method for treating occult a choroidal neovascular lesion in a subject comprising providing photodynamic therapy to a subject assessed as having either or both of (a) a small lesion or (b) poor visual acuity.
2. The method of claim 1 wherein said subject was assessed by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.
3. The method of claim 1 wherein the visual acuity of the subject at baseline is less than 65 letters.
4. The method of claim 1 wherein the small lesion has a size less than about 4-5 disc areas.
5. The method of claim 1 wherein the small lesion has a size less than about 4 disc areas.
6. The method of claim 1, wherein the occult CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).
7. The method of claim 1 wherein said PDT comprises the administration of a photosensitizer (PS).
8. The method of claim 7, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m² (PS/body surface area of subject).
9. The method of claim 8, wherein the PS is administered at a concentration of 6 mg/m².
10. The method of claim 9, wherein the PS is a green porphyrin.
11. The method of claim 10, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.
12. The method of claim 11, wherein the green porphyrin is BPD-MA.
13. The method of claim 10, wherein the PS is coupled to a specific binding ligand.

14. The method of claim 7, wherein the PS is formulated with a carrier.

15. The method of claim 14, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.

16. The method of claim 1, wherein said PDT comprises irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.

17. The method of claim 16, wherein the irradiation provides between 12.5 J/cm^2 and 100 J/cm^2 .

18. The method of claim 17, wherein said irradiation occurs between 5 to 30 minutes after administration of a photosensitizer.

19. The method of claim 7, wherein the PS is administered at a concentration ranging between about $10 \mu\text{g/kg}$ to 100mg/kg (PS/body weight of subject).